伊豆津 宏二 いづつ こうじ 先生

来歴等

略歴

1994年 東京大学医学部 医学科 卒業
1994年 関東逓信病院（現・NTT東日本関東病院） 内科 研修医
1996年 関東逓信病院（現・NTT東日本関東病院） 血液内科 専修医
2001年 東京大学大学院 医学系研究科 修了（医学博士）
2003年 東京大学医学部附属病院 血液・腫瘍内科 助手
2007年 NTT東日本関東病院 血液内科 医長
2010年 国家公務員共済組合連合会 虎の門病院 血液内科 医長
2011年 国家公務員共済組合連合会 虎の門病院 血液内科 部長（リンパ腫担当）
2017年 国立がん研究センター中央病院 血液腫瘍科 科長

論文

• 1. TFH phenotype and response to tucidinostat in relapsed/refractory PTCL: analysis of patients from a phase IIb trial. Int J Hematol. 2026 Jun 9. doi: 10.1007/s12185-026-04237-8. Online ahead of print. PMID: 42262647.

  Izutsu K Fujimoto A, Rai S, Maruyama D, Ohmachi K, Yokohama A, Tsukasaki K, Uchida T, Kuroda J, Choi I, Hidaka M, Ando J, Sakamoto T, Kato H, Minami H, Yoshida S, Yamamoto M, Gillings M, Onogi H, Takeuchi K.

• 2. Atezolizumab for relapsed/refractory extranodal NK/T-cell lymphoma: the phase II NCCH1903/ATTACK trial. Blood Adv. 2026 May 20.

  Makita S, Koya J, Suzuki Y, Nishikori M, Fukuhara N, Miyagi Maeshima A, Hirkawa A, Ito Y, Kogure Y, Chiba K, Okada A, Shiraishi Y, Kawashima S, Nagasaka Y, Fujimoto A, Nagai H, Takeuchi K, Kataoka K, Izutsu K.

• 3. Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenström macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trial. Lancet Haematol. 2026 May;13(5):e284-e296.

  Palomba ML, Patel MR, Eyre TA, Jurczak W, Lewis D, Gastinne T, Ma S, Cohen JB, Patel K, Brown JR, Scarfò L, Munir T, Lech-Maranda E, Hoffmann MS, Ujjani CS, Fakhri B, Wang ML, Izutsu K, Nagai H, Tam CS, Rhodes JM, Vose J, McKinney M, Gerson JN, Barve MA, Kuss B, Koh Y, Barrett A, Treon SP, Castillo JJ, Seymour JF, Ruppert AS, McNeely SC, Walgren RA, Tsai DE, Bao K, Nair B, Woyach J, Cheah CY.

• 4. Clonal analysis of a case with fluid overload-associated large B-cell lymphoma evolving from primary large B-cell lymphoma of the central nervous system. Ann Hematol. 2026 Mar 11;105(4):170.

  Ito Y, Kogure Y, Maeshima AM, Hosoba R, Fukuhara S, Munakata W, Chiba K, Okada A, Shiraishi Y, Narita Y, Izutsu K, Kataoka K.

• 5. Lisocabtagene maraleucel in patients with relapsed or refractory marginal zone lymphoma (TRANSCEND FL): primary analysis results from the global, multicohort, single-arm, phase 2 study. Lancet. 2026 Mar 7;407(10532):963-975.

  Palomba ML, Schuster SJ, Karmali R, Skarbnik AP, Abramson JS, Ardeshna K, Borchmann P, Hill BT, García-Sancho AM, Marcacci G, Rapoport AP, Cartron G, Fleury I, Izutsu K, Kamdar M, Mielke S, Barbui AM, Ortega JLR, Nastoupil LJ, Ahmed S, Bar M, Diaz L, Furustrand U, Diab V, Vedal M, Avilion A, Kumar J, Nishii R, Colicino S, Morschhauser F.

• 6. Tafasitamab as Monotherapy or in Combination in Japanese Patients With B-Cell Non-Hodgkin Lymphoma: Results From the Phase 1b J-MIND Study. Cancer Sci. 2026 Apr;117(4):1093-1105.

  Izutsu K, Fukuhara N, Yuda J, Suehiro Y, Kusumoto S, Casadebaig ML, Suzukawa K, Fukushima K. (corresponding author)

• 7. Three-year follow-up of epcoritamab therapy in Japanese patients with relapsed/refractory follicular lymphoma in EPCORE NHL-3. Int J Hematol. 2026 Jan 18. doi: 10.1007/s12185-025-04139-1. Online ahead of print. PMID: 41548170.

  Izutsu K, Akahane D, Toubai T, Saito T, Mishima Y, Fujisaki T, Nishikori M, Kumode T, Suehiro Y, Ishitsuka K, Patah P, Takahashi A, Månsson BD, Favaro E, Fukuhara N. (corresponding author)

• 8. Efficacy and safety of fixed-duration venetoclax plus obinutuzumab in untreated Japanese CLL and SLL: a phase 2 study. Int J Hematol. 2026 Feb;123(2):225-232.

  Izutsu K, Watanabe M, Toubai T, Tsukamoto T, Maruyama D, Kumode T, Fukuhara N, Ogawa N, Satomi N, Nishimura Y, Honda H, Chyla B, Takizawa J.

• 9. Long-term outcomes of venetoclax and ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma. Int J Clin Oncol. 2025 Nov;30(11):2352-2361.

  Goto H, Ito S, Kizaki M, Yamaguchi M, Fukuhara N, Kato K, Saito T, Terui Y, Soshin T, Satomi-Tsushita N, Honda H, Qian C, Izutsu K.

• 10. Subcutaneous epcoritamab monotherapy in Japanese patients with relapsed or refractory follicular lymphoma: primary results of the EPCORE NHL-3 trial. Leuk Lymphoma. 2025 Oct;66(10):1913-1921.

  Izutsu K, Akahane D, Toubai T, Saito T, Mishima Y, Fujisaki T, Nishikori M, Kumode T, Suehiro Y, Ishitsuka K, Conlon R, Takahashi A, D'Angelo Månsson B, Favaro E, Fukuhara N. (corresponding author)

• 11. Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study. J Clin Oncol. 2025 20; 43(24):2671-2678.

  Kamdar M, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, Ibrahimi S, Mielke S, Mutsaers P, Hernandez-Ilizaliturri F, Izutsu K, Morschhauser F, Lunning M, Chow VA, Montheard S, Santamaria J, Colicino S, Ogasawara K, Stepan L, Liu FF, Abramson JS.

• 12. Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2024 Dec;25(12):1602-1613.

  Zinzani PL, Izutsu K, Mehta-Shah N, Barta SK, Ishitsuka K, Córdoba R, Kusumoto S, Bachy E, Cwynarski K, Gritti G, Prica A, Jacobsen E, Feldman T, Guillermin Y, Ennishi D, Yoon DH, Domenech ED, Zain J, Wang J, Kim JS, Poel MV, Jin J, Wu S, Chen Y, Moriyama T, Inoue A, Nakajima K, Horwitz SM.

• 13. Valemetostat monotherapy in patients with relapsed or refractory non-Hodgkin lymphoma: a first-in-human, multicentre, open-label, single-arm, phase 1 study. Lancet Oncol. 2024 Dec;25(12):1589-1601.

  Maruyama D, Jacobsen E, Porcu P, Allen P, Ishitsuka K, Kusumoto S, Narita T, Tobinai K, Foss F, Tsukasaki K, Feldman T, Imaizumi Y, Izutsu K, Morishima S, Yamauchi N, Yuda J, Brammer JE, Kawamata T, Ruan J, Nosaka K, Utsunomiya A, Wang J, Zain J, Kakurai Y, Yamauchi H, Hizukuri Y, Biserna N, Tachibana M, Inoue A, Horwitz SM.

• 14. Tazemetostat for relapsed/refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan: 3-year follow-up for a phase II study. Int J Hematol. 2024; 120(5):621-630.

  Izutsu K, Ando K, Nishikori M, Shibayama H, Goto H, Kuroda J, Kato K, Imaizumi Y, Nosaka K, Sakai R, Abe M, Hojo S, Nakanishi T, Rai S. (corresponding author)

• 15. Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study. Nat Med. 2024; 30 (8):2199-2207.

  Morschhauser F, Dahiya S, Palomba ML, Martin Garcia-Sancho A, Reguera Ortega JL, Kuruvilla J, Jäger U, Cartron G, Izutsu K, Dreyling M, Kahl B, Ghesquieres H, Ardeshna K, Goto H, Barbui AM, Abramson JS, Borchmann P, Fleury I, Mielke S, Skarbnik A, de Vos S, Kamdar M, Karmali R, Viardot A, Farazi T, Fasan O, Lymp J, Vedal M, Nishii R, Avilion A, Papuga J, Kumar J, Nastoupil LJ.

• 16. Phase 2 study of ibrutinib plus venetoclax in Japanese patients with relapsed/refractory mantle cell lymphoma. Int J Clin Oncol. 2024 Feb;29(2):232-240.

  Goto H, Ito S, Kizaki M, Yamaguchi M, Fukuhara N, Kato K, Saito T, Terui Y, Okubo S, Soshin T, Zeng J, Honda H, Badawi M, Ross JA, Izutsu K.

• 17. Subcutaneous epcoritamab monotherapy in Japanese adults with relapsed/refractory diffuse large B-cell lymphoma. Cancer Sci. 2023 Dec;114(12):4643-4653.

  Izutsu K, Kumode T, Yuda J, Nagai H, Mishima Y, Suehiro Y, Yamamoto K, Fujisaki T, Ishitsuka K, Ishizawa K, Ikezoe T, Nishikori M, Akahane D, Fujita J, Dinh M, Soong D, Noguchi H, Buchbjerg JK, Favaro E, Fukuhara N. (corresponding author)

• 18. Measurable residual disease in Japanese patients with relapsed or refractory chronic lymphocytic leukemia treated with venetoclax. Int J Hematol. Int J Hematol. 2023 Oct;118(4):526-528.

  Izutsu K, Yamamoto K, Kato K, Ishikawa T, Fukuhara N, Terui Y, Choi I, Okubo S, Ogawa N, Sakai M, Nishimura Y, Chyla B, Sun Y, Maruyama D.

• 19. Pirtobrutinib in Covalent BTK-Inhibitor Pre-treated Mantle Cell Lymphoma. J Clin Oncol. 2023 Aug 20;41(24):3988-3997.

  Wang ML, Jurczak W, Zinzani PL, Eyre TA, Cheah CY, Ujjani CS, Koh Y, Izutsu K, Gerson JN, Flinn I, Tessoulin B, Alencar AJ, Ma S, Lewis D, Lech-Maranda E, Rhodes J, Patel K, Maddocks K, Lamanna N, Wang Y, Tam CS, Munir T, Nagai H, Hernandez-Ilizaliturri F, Kumar A, Fenske TS, Seymour JF, Zelenetz AD, Nair B, Tsai DE, Balbas M, Walgren RA, Abada P, Wang C, Zhao J, Mato AR, Shah NN.

• 20. An Open-Label, Single-Arm, Phase 2 Trial of Valemetostat in Relapsed or Refractory Adult T-Cell Leukemia/Lymphoma. Blood. 2023; 141(9):1159-1168.

  Izutsu K, Makita S, Nosaka K, Yoshimitsu M, Utsunomiya A, Kusumoto S, Morishima S, Tsukasaki K, Kawamata T, Ono T, Rai S, Katsuya H, Ishikawa J, Yamada H, Kato K, Tachibana M, Kakurai Y, Adachi N, Tobinai K, Yonekura K, Ishitsuka K. (corresponding author)

• 21. Lisocabtagene maraleucel, a CD19-directed chimeric antigen receptor T-cell therapy, versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma: results from the randomised, open-label TRANSFORM phase 3 study. Lancet. 2022; 399(10343):2294-2308.

  Kamdar M, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, Ibrahimi S, Mielke S, Mutsaers P, Hernandez-Ilizaliturri F, Izutsu K, Morschhauser F, Lunning M, Maloney DG, Crotta A, Montheard S, Previtali A, Stepan L, Ogasawara K, Mack T, Abramson JS; TRANSFORM Investigators.

• 22. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. N Engl J Med. 2022; 386:351-363.

  Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trněný M, Sharman JP, Herbaux C, Burke JM, Matasar M, Rai S, Izutsu K, Mehta-Shah N, Oberic L, Chauchet A, Jurczak W, Song Y, Greil R, Mykhalska L, Bergua-Burgués JM, Cheung MC, Pinto A, Shin HJ, Hapgood G, Munhoz E, Abrisqueta P, Gau JP, Hirata J, Jiang Y, Yan M, Lee C, Flowers CR, Salles G.

• 23. Safety and Antitumor Activity of Acalabrutinib for Relapsed/Refractory B-cell Malignancies: A Japanese Phase I Study. Cancer Sci. 2021; 112(6):2405-2415.

  Izutsu K, Ando K, Ennishi D, Shibayama H, Suzumiya J, Yamamoto K, Ichikawa S, Kato K, Kumagai K, Patel P, Iizumi S, Hayashi N, Kawasumi H, Murayama K, Nagai H.

• 24. Primary human herpesvirus 8–negative effusion-based lymphoma: a large B-cell lymphoma with favorable prognosis. Blood Adv. 2020; 4(18):4442-4450.

  Kaji D, Ota Y, Sato Y, Nagafuji K, Ueda Y, Okamoto M, Terasaki Y, Tsuyama N, Matsue K, Kinoshita T, Yamamoto G, Taniguchi S, Chiba S, Ohshima K, Izutsu K. (corresponding author)

著書

• 1. 血液のがんがわかる本 リンパ腫・白血病・多発性骨髄腫（伊豆津宏二監修・講談社・2023年）